Correspondence 0001213900-24-004594 from BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc.
Date: Jan. 18, 2024 · CIK: 0001869105 · Accession: 0001213900-24-004594
AI Filing Summary & Sentiment
Referenced dates: January 10, 2024
Show Raw Text
CORRESP
1
filename1.htm
January 18,
2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance,
Office of Real Estate & Construction
100 F Street, NE
Washington, D.C. 20549
Attn: Paul Cline
Isaac Esquivel
Ronald E. Alper
Pam Howell
Re: Helix Acquisition Corp. II
Draft Registration Statement on Form S-1
Submitted December 20, 2023
CIK No. 0001869105
Ladies and Gentlemen:
On behalf of our client, Helix Acquisition Corp.
II, a Cayman Islands exempted company (the “Company”), we are writing to submit the Company’s responses
to the comments of the staff of the Division of Corporation Finance of the United States Securities and Exchange Commission (the “Staff”)
with respect to the above-referenced draft registration statement submitted on December 20, 2023 (the “Draft Registration
Statement”), contained in the Staff’s letter dated January 10, 2024 (the “Comment Letter”).
The Company has filed via EDGAR its Registration
Statement on Form S-1 (“Registration Statement”), which reflects the Company’s responses to the comments
received from the Staff and certain updated information. For ease of reference, each comment contained in the Comment Letter is printed
below in bold and is followed by the Company’s response. All page references in the responses set forth below refer to page numbers
in Registration Statement as filed.
Draft Registration Statement on Form S-1 submitted December 20,
2023
We may issue our shares to investors in connection with our initial
business combination, page 47
1. We note your disclosure here and your references to PIPE transactions elsewhere. Please clearly disclose their impact to you and
investors. To the extent you may utilize PIPE transactions, disclose that the agreements are intended to ensure a return on investment
to the investor in return for funds facilitating the sponsor’s completion of the business combination or providing sufficient liquidity.
Additionally, please also disclose that these arrangements result in costs particular to the de-SPAC process that would not be anticipated
in a traditional IPO. Lastly, please clarify here and throughout the prospectus whether the PIPE transactions may occur at a price below
the IPO price of $10 per share and if so, the resultant risks.
Response: The Company has revised the disclosure on page 47 of the
Registration Statement to address the Staff’s comment.
The new 1% U.S. federal excise tax on stock buybacks could be
imposed, page 69
2. We note that this risk factor describes the potential material
effect on your shareholders of the stock buyback excise
tax enacted as part of the Inflation Reduction Act of August 2022. Please also describe the
risks of the excise tax applying to redemptions in connection with:
● liquidations
that are not implemented to fall within the meaning of “complete liquidation”
in Section 331 of the Internal Revenue Code;
● extensions,
depending on the timing of the extension relative to when the SPAC completes a de-SPAC or
liquidates; and
● de-SPACs,
depending on the structure of the de-SPAC transaction.
Response:
The Company acknowledges the Staff’s comment and has revised the risk factor regarding the excise tax on page 69 of the Registration
Statement to discuss the risks of the excise tax applying to redemptions in connection with liquidations, extensions and business combinations.
Our
amended and restated memorandum and articles of association provide that the courts of the
Cayman
Islands will be the exclusive, page 72
3. Please
reconcile the disclosure in this risk factor that “the forum selection provision in
our amended and restated memorandum and articles of association will not apply to actions
or suits brought to enforce any liability or duty created by the Securities Act, Exchange
Act or any claim for which the federal district courts of the United States are, as a matter
of the laws of the United States, the sole and exclusive forum for determination of such
a claim” with the disclosure on page 139 that “our amended and restated memorandum
and articles of association also provide that, unless we consent in writing to the selection
of an alternative forum, to the fullest extent permitted by law, the federal district courts
of the United States will be the exclusive forum for the resolution of any complaint asserting
a cause of action arising under the federal securities laws of the United States, including
those arising under the Securities Act or Exchange Act.”
Response:
The Company has revised the disclosure on page 139 of the Registration Statement to address the Staff’s comment.
Permitted
Purchases of Our Securities, page 97
4. We
note that unlike traditional SPACs, your offering does not include warrants. Please explain
the references to the potential purchase of public warrants in this section or remove.
Response:
The Company has removed the references to the potential purchase of public warrants starting on page 97 of the Registration Statement
as such disclosure is not applicable.
2
Directors’
Fiduciary Duties and Conflicts of Interest, page 118
5. Please
expand your disclosure in this section to highlight the financial conflicts of interest of
your sponsor, officers, directors, advisors and/or your or their affiliates, as the case
may be. For example, highlight, to the extent applicable, conflicts arising from ownership
of the founder shares and private placement shares, including that:
● because
of the low price they paid for the founder shares, your sponsor and your officers and directors
may make a substantial profit even if the company selects an acquisition target that subsequently
declines in value and is unprofitable for public investors;
● if
you do not consummate a business combination within the time required, the founder shares,
private placement units, and their underlying securities will expire worthless; and
● highlight
whether employment or consulting agreements negotiated with a target business in connection
with a business combination, or other agreements providing for compensation following an
initial business combination, may cause your officers and directors to have a conflict of
interest.
Response:
The Company has revised and expanded the disclosure on page 121 of the Registration Statement to address the Staff’s comment.
Principal
Shareholders, page 123
6. Please
revise to include Bihua Chen in the beneficial ownership table and include the shares owned
through Helix Holdings II LLC, your sponsor, as reflected in footnote three to the table.
Please also revise the amount held by officers and directors as a group.
Response:
The Company has revised the beneficial ownership table on page 123 of the Registration Statement to address the Staff’s comment.
Signatures,
page II-4
7. Please
include the signatures of the majority of the board of directors. See Instruction 1 to Signatures
to Form S-1.
Response:
The Company acknowledges the Staff’s comment and has revised the disclosure starting on page 113 of the Registration Statement
to clarify that Bihua Chen is the only member of the board of directors of the Company at the time of filing of the Registration Statement.
*
* *
3
Please
do not hesitate to contact Joel L. Rubinstein at (212) 819-7642 of White & Case LLP with any questions or comments regarding this
letter.
Sincerely,
/s/ White & Case LLP
White
& Case LLP
cc: Bihua
Chen, Helix Acquisition Corp. II
4